Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK’s NICE Backs Two Microsphere Products For Liver Cancer But Says No To Another

Executive Summary

Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.

You may also be interested in...



Boston Scientific TheraSphere Liver Cancer Treatment Succeeds In EPOCH Trial

Results showed that patients were less likely to exhibit disease progression, or die, following treatment with beta-emitted microspheres.

In A First, FDA Approves Radioembolization Treatment For Liver Cancer In US

Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.

Seventeen And Counting – Bumper Crop Of New EU Filings

Orphan drugs and COVID-19 products are among the latest filings under review by the European Medicines Agency for potential pan-EU approval.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143587

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel